Search Results - "Demey, W."

Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial) by Piessevaux, H., Demey, W., Bols, A., Janssens, J., Polus, M., Rezaei Kalantari, H., Laurent, S., Demols, A., Humblet, Y., Deboever, G., Kargar Samani, K., Ferrante, M., Monsaert, E., Rondou, T., van Laethem, J.-L., Tejpar, S.

Get full text

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future by Geukens, T., Brandão, M., Laenen, A., Collignon, J., Van Marcke, C., Louviaux, I., Demey, W., Van Wambeke, S., Schrijvers, D., Lecomte, S., Mebis, J., Rutten, A., Fontaine, C., Lybaert, W., Aspeslagh, S., Goeminne, J.-C., Van Den Bulck, H., Seront, E., De Backer, L., De Roock, W., Ignatiadis, M., Prenen, H., Van Beckhoven, D., Heijlen, M., Verheezen, J., Rottey, S., Punie, K., de Azambuja, E.

“…Solid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective…”
Get full text

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment by Thouvenin, J., Van Marcke, C., Decoster, L., Raicevic, G., Punie, K., Vandenbulcke, M., Salgado, R., Van Valckenborgh, E., Maes, B., Joris, S., Steichel, D. Vander, Vranken, K., Jacobs, S., Dedeurwaerdere, F., Martens, G., Devos, H., Duhoux, F.P., Rasschaert, M., Pauwels, P., Geboes, K., Collignon, J., Tejpar, S., Canon, J.-L., Peeters, M., Rutten, A., Van de Mooter, T., Vermeij, J., Schrijvers, D., Demey, W., Lybaert, W., Van Huysse, J., Mebis, J., Awada, A., Claes, K.B.M., Hebrant, A., Van der Meulen, J., Delafontaine, B., Bempt, I. Vanden, Maetens, J., de Hemptinne, M., Rottey, S., Aftimos, P., De Grève, J.

“…PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim…”
Get full text

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma by Powles, Thomas, Park, Se Hoon, Voog, Eric, Caserta, Claudia, Valderrama, Begoña P, Gurney, Howard, Kalofonos, Haralabos, Radulović, Siniša, Demey, Wim, Ullén, Anders, Loriot, Yohann, Sridhar, Srikala S, Tsuchiya, Norihiko, Kopyltsov, Evgeny, Sternberg, Cora N, Bellmunt, Joaquim, Aragon-Ching, Jeanny B, Petrylak, Daniel P, Laliberte, Robert, Wang, Jing, Huang, Bo, Davis, Craig, Fowst, Camilla, Costa, Nuno, Blake-Haskins, John A, di Pietro, Alessandra, Grivas, Petros

“…Patients with advanced or metastatic urothelial cancer who had had a response to platinum-based chemotherapy were randomly assigned to best supportive care…”
Get full text

181P GeNeo: Agnostic comprehensive genomic profiling versus limited panel organ-directed next-generation sequencing within the Belgian PRECISION initiative by Aftimos, P.G., Punie, K., Decoster, L., Van Marcke de Lummen, C., Hebrant, A., Raicevic, G., Van Valckenborgh, E., Maes, B., Maetens, J., Collignon, J.J., van den Mooter, T.F.A., Fried-Vermeij, J., Demey, W., Tejpar, S., Peeters, M., Canon, J-L., Lybaert, W., Mebis, J., Rottey, S., De Grève, J.

Get full text

468P PANIB 20139173: Randomized, multicentre phase II trial comparing fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus panitumumab versus FOLFOX plus bevacizumab in patients with previously untreated, RAS wild-type (WT) metastatic colorectal cancer (mCRC) by Janssens, K., Fransen, E., Rolfo, C.D., Lybaert, W., Demey, W., Decaestecker, J., Hendrickx, K., Kalantari, H., Op de Beeck, K., Van Camp, G., Peeters, M.

Get full text

PO-1383 Neoadjuvant versus definitive chemoradiation for esophageal cancer: a retrospective analysis by Joye, I., Vermeulen, S., Op de Beeck, T., Geudens, N., Vandamme, T., Simoens, M., Botelberge, T., Valk, J., de Maat, M., Lybaert, W., Demey, W., Machiels, M., Nevens, D., Billiet, C., Meijnders, P., Mercier, C., Vanderkam, S., Weytjens, R., Van Laere, S.

Get full text

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis by Mayrhofer, Markus, De Laere, Bram, Whitington, Tom, Van Oyen, Peter, Ghysel, Christophe, Ampe, Jozef, Ost, Piet, Demey, Wim, Hoekx, Lucien, Schrijvers, Dirk, Brouwers, Barbara, Lybaert, Willem, Everaert, Els, De Maeseneer, Daan, Strijbos, Michiel, Bols, Alain, Fransis, Karen, Oeyen, Steffi, van Dam, Pieter-Jan, Van den Eynden, Gert, Rutten, Annemie, Aly, Markus, Nordström, Tobias, Van Laere, Steven, Rantalainen, Mattias, Rajan, Prabhakar, Egevad, Lars, Ullén, Anders, Yachnin, Jeffrey, Dirix, Luc, Grönberg, Henrik, Lindberg, Johan

“…There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive…”
Get full text

704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 by Grivas, P., Park, S.H., Voog, E., Caserta, C., Perez Valderrama, B., Gurney, H., Kalofonos, H., Radulovic, S., Demey, W., Ullén, A., Loriot, Y., Sridhar, S.S., Tsuchiya, N., Kopyltsov, E., Gupta, S., Huang, B., Costa, N., Blake-Haskins, J.A., di Pietro, A., Powles, T.B.

Get full text

1804PEffect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial) by Piessevaux, H, Demey, W, Bols, A, Janssens, J, Polus, M, Rezaei Kalantari, H, Laurent, S, Demols, A, Humblet, Y, Deboever, G, Kargar Samani, K, Ferrante, M, Monsaert, E, Rondou, T, van Laethem, J-L, Tejpar, S

Get full text

772 Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel? by Van Praet, C, Rottey, S, Van Hende, F, Pelgrims, G, Demey, W, Van Aelst, F, Wynendaele, W, Gil, T, Schatteman, P, Filleul, B, Schallier, D, Machiels, J-P, Schrijvers, D, Everaert, E, D'Hondt, L, Werbrouck, P, Vermeij, J, Mebis, J, Clausse, M, Rasschaert, M, Van Erps, J, Verheezen, J, Van Haverbeke, J, Goeminne, J-C, Lumen, N

Get full text

Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer by Powles, Thomas, Park, Se Hoon, Voog, Eric, Caserta, Claudia, Valderrama, Begoña P, Gurney, Howard, Kalofonos, Haralabos, Radulovic, Sinisa, Demey, Wim, Ullén, Anders, Loriot, Yohann, Sridhar, Srikala S, Tsuchiya, Norihiko, Kopyltsov, Evgeny, Sternberg, Cora N, Bellmunt, Joaquim, Aragon-Ching, Jeanny B, Petrylak, Daniel P, Laliberte, Robert J, Huang, Bo, Costa, Nuno, Blake-Haskins, John A, Grivas, Petros

“…This is a plain language summary of an article originally published in . It is about initial results (collected in October 2019) from the JAVELIN Bladder 100…”
Get full text

Effect of hospital volume on quality of care and outcome after rectal cancer surgery by Leonard, D., Penninckx, F., Kartheuser, A., Laenen, A., Van Eycken, E.

“…Background Research on the relationship between hospital volume and quality of care in the treatment of rectal cancer is limited. Methods Process and outcome…”
Get full text

Scoring the quality of total mesorectal excision for the prediction of cancer-specific outcome by Leonard, D., Penninckx, F., Laenen, A., Kartheuser, A.

“…Aim A three‐grade system for macroscopic evaluation of the resection plane is used to describe the quality of total mesorectal excision (TME). In several…”
Get full text

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer by De Laere, Bram, Rajan, Prabhakar, Grönberg, Henrik, Dirix, Luc, Lindberg, Johan

Get more information

Review of the quality of total mesorectal excision does not improve the prediction of outcome by Demetter, P., Jouret-Mourin, A., Silversmit, G., Vandendael, T., Sempoux, C., Hoorens, A., Nagy, N., Cuvelier, C., Van Damme, N., Penninckx, F.

“…Aim A fair to moderate concordance in grading of the total mesorectal excision (TME) surgical specimen by local pathologists and a central review panel has…”
Get full text

Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 by Grivas, P, Park, SH, Voog, E, Caserta, C, Valderrama, BP, Gurney, H, Kalofonos, H, Radulovic, S, Demey, W, Ullen, A, Loriot, Y, Sridhar, SS, Tsuchiya, N, Kopyltsov, E, Gupta, S, Huang, B, Costa, N, Blake-Haskins, JA, di Pietro, A, Powles, TB

Get full text

Maintenance avelumab plus best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis by Powles, T, Park, SH, Voog, E, Caserta, C, Valderrama, BP, Gurney, H, Kalofonos, H, Radulovic, S, Demey, W, Ullen, A, Loriot, Y, Sridhar, SS, Tsuchiya, N, Kopyltsov, E, Sternberg, CN, Bellmunt, J, Aragon-Ching, JB, Petrylak, DP, di Pietro, A, Grivas, P

Get full text

Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project by Penninckx, Freddy, Fieuws, Steffen, Beirens, Koen, Demetter, Pieter, Ceelen, Wim, Kartheuser, Alex, Molle, Gaetan, Van de Stadt, Jean, Vindevoghel, Koen, Van Eycken, Elizabeth

“…The abdominoperineal excision (APE) rate, a quality of care indicator in rectal cancer surgery, has been criticised if not adjusted for confounding factors…”
Get more information

Intrahepatic mitomycin C as treatment of breast cancer hepatic metastasis by Demey, W., Wildiers, H., Maleux, G., Clement, P., Heye, S., Debruyne, P., Van Oosterom, A., Paridaens, R.

“…Abstract only 10690 Background: Because of increasing survival due to improving systemic treatment, liver metastasis represents a major and increasing cause of…”
Get full text